???We are pleased to add this next generation inhaler to OPKO???s growing product portfolio,??? stated Phillip Frost, M.D., OPKO???s CEO and Chairman. ???We expect this innovative device to play a valuable role in the improvement of therapy for asthma, chronic obstructive pulmonary disease, cystic fibrosis and other respiratory diseases.